Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi (azilsartan).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Third Circuit backs pharma firm in antitrust clash

13 December 2022 Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

1 July 2021 Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.

Big Pharma

Genevant signs $600m liver fibrosis deal with Takeda

18 March 2021 Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.